Navigation Links
Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Date:8/7/2012

INDIANAPOLIS, Aug. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced data from a Phase III trial comparing the effects of FORTEO® (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study showed no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a numeric rating scale in each treatment group.[1] However, there were statistically significant differences in favor of FORTEO in some exploratory measures, including greater increases in bone mineral density (BMD) and fewer patients with new vertebral fractures. The results of the study are published in the August issue of Osteoporosis International.

"With many available options to treat osteoporosis, this study is important because it compares two established osteoporosis medicines in a direct head-to-head design," said lead investigator Peyman Hadji, M.D., department head, endocrinology, osteoporosis and reproductive medicine at Philipps-University of Marburg.

At six months, more than half of patients in both treatment groups reported a 30 percent or greater reduction in worst back pain (FORTEO – 59.2 percent, risedronate – 57.4 percent; p=0.64).[1] (A 30 percent or greater reduction is considered a clinically meaningful change.)[1] There were no statistically significant differences between treatments in the secondary and exploratory endpoints of at least a 30 percent reduction in worst or average back pain at six, 12 or 18 months;[1] quality of life; disability; days of bed rest; days of disability; and amount of concomitant analgesics used. Significantly fewer patients treated with FORTEO experienced a worsening of average back pain between six a
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DUBLIN , Sept. 22, 2014 ... the "PCSK9 and Other Novel Hypercholesterolemia Drugs" ... indicate that there is a high cholesterol burden despite ... Out of all the available options, statins have been ... concluded that reduction of plasma LDL cholesterol (LDLC) is ...
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... and fiscal 2014 ended July 31, 2014 on Monday, September ... to discuss the results at 11:00 AM ET. Participating in ... Andrew A. Krakauer , President and CEO; Jorgen ... A. Sheldon , Senior Vice President, CFO and Treasurer; and ...
Breaking Medicine Technology:PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2
... N.J., Oct. 15 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., has received approval from the United States ... Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and ... The ANDA was acquired as part of Watson,s acquisition ...
... Inc. (Nasdaq: REGN ) will webcast its ... Industry Conference on Friday, October 22, 2010.  The presentation ... may be accessed through the Company,s web site, ... version of the presentation will be available after the ...
Cached Medicine Technology:Watson's Generic Version of Lotrel ® Receives FDA Approval 2
(Date:9/22/2014)... new study pulls back the curtain on one of ... payment and income between physicians who perform operations, procedures ... to perception, the research indicates, the physician payment system ... procedure-performing doctors. , The new findings counter the widely ... minute explains why doctors who perform procedures often earn ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... care units (NICU) set up private rooms for parents to ... Researchers at one children,s hospital found that preemies gained weight ... NICU switched from the traditional "open-bay" layout to private rooms ... the journal Pediatrics , add to evidence that private ...
(Date:9/22/2014)... Up to 40 percent of patients undergoing breast cancer ... remove all the cancerous tissue in the initial operation. ... successfully tested a tool they developed that will help ... thereby decreasing the chances for repeat operations. ... of September 22, 2014 in the Proceedings of ...
(Date:9/22/2014)... ON (September 22, 2014) McMaster scientists have found ... new class of antibiotics. , Although dozens of ... at how a certain part of bacteria are created, ... it. , The discovery is important as there ... making the cures for infections ineffective. The World Health ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
Breaking Medicine News(10 mins):Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:The fine line between breast cancer and normal tissues 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2
... MONDAY, Jan. 16 (HealthDay News) -- Persistent pain, eating problems ... survivors of head and neck cancer, a new study finds. ... issue of the journal Archives of Otolaryngology -- Head ... were diagnosed with head and neck cancer from 1995 to ...
... ten Canadians cannot afford to take their prescription drugs as ... of British Columbia and the University of Toronto. ... Canadian Medical Association Journal ) is the first to examine ... drugs in Canada. Researchers from UBC,s Centre for Health Services ...
... most severe cases of Lupus (systemic lupus erythemathosus), an ... the activity of some critical genes of the immune ... Italian researchers at the Catholic University of Sacred Heart ... the accelerator of the car and boosts the pathological ...
... British Columbia have found a new way to block infection ... could lead to new therapies for those affected by this ... worldwide suffer from hepatitis C, the disease caused by chronic ... of the leading causes of liver cancer and liver transplant ...
... Scientists working at the Medical Research Council have identified ... pre-cancerous cells in the esophagus, a condition called Barrett,s ... these cells before they develop into esophageal cancer. These ... have important implications for patients and may help to ...
... -- Soccer players need to use the correct techniques ... redirect the ball -- to prevent possible brain injury, researchers ... between the sport and brain damage, Dr. Alejandro Spiotta and ... moving at high speeds when they come into contact with ...
Cached Medicine News:Health News:Many Head and Neck Cancer Survivors Face Eating Problems 2Health News:1 in 10 Canadians cannot afford prescription drugs: UBC study 2Health News:A genetic accelerator hits the gas on autoimmune diseases 2Health News:UBC researchers identify potential new therapy approach for hepatitis C 2Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:Heading Soccer Balls Could Injure Brain 2
... new thinking to address common problems associated ... mm diameter outer arthroscope sheath, the shorter, ... Videoscope has superior access and mobility in ... and especially in the elbow and ankle. ...
... is the second generation of the lens ... technology allows one-handed delivery of the C11UB ... colored plunger allows better visualization and is ... insertion. The modified 55-degree beveled tip eases ...
... Heart 2006 is a long-term Transtelephonic ... This device is the solution ... symptoms and their correlation to the ... it provides 2 lead loop recording ...
... cable and 4 metal chest electrodes ... 3-step procedure enabling a patient to ... lead ECG through a simple change ... seconds per lead and 10 seconds ...
Medicine Products: